Drug
Ursodoxicoltaurine clinical trials
Also written Tauroursodeoxycholic acid.
- studies test it
- 25
- open now
- 5
- in phase 3
- 5
- first study started
- 1997
Keep track of what changes. Save the ursodoxicoltaurine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2021 | 2 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 5
- Phase 4
- 1
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 25
Humanitas Mirasole SpA (2) · Fondazione IRCCS Policlinico San Matteo di Pavia (2) · Washington University School of Medicine (2) · Children's Hospital Medical Center, Cincinnati (2) · Robin Goland, MD (1) · Johns Hopkins University (1) · Brigham and Women's Hospital (1) · University of Missouri-Columbia (1)
Often tested with
Tested in the same studies.
Doxycycline (3) · Phenylbutyric acid (1) · Arachidonic Acid (1) · Camrelizumab (1)
Studies
Open first, then newest update. How each study uses ursodoxicoltaurine is read from its arms, and is right about nine times in ten.
Testing it · 25
- TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity IndexNot yet recruitingPhase 2Peking University First HospitalNCT07517276Written as tauroursodeoxycholic acid (TUDCA)
- Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingPhase 2Fudan UniversityNCT07100392Written as tauroursodeoxycholic acid (TUDCA)
- Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective StudyNot yet recruitingPhase 2Tongji HospitalNCT07064668Written as TUDCA (Tauroursodeoxycholic Acid) Supplementation
- Targeting Endoplasmic Reticulum Stress in Human HypertensionRecruitingPhase 1/2University of North Texas Health Science CenterNCT06025630Written as TUDCA
- Effect of Oral Supplements for Influenza Vaccine ResponseNot yet recruitingNot applicableTsinghua UniversityNCT06827873Written as TUDCA (Tauroursodeoxycholic Acid) Supplementation
- Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.WithdrawnPhase 2University of Alabama at BirminghamNCT07457632Written as Tauroursodeoxycholate (TUDCA)
- Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 DiabetesCompletedPhase 2Robin Goland, MDNCT02218619Written as Tauroursodeoxycholic Acid (TUDCA)
- A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by TransthyretinCompletedPhase 3Fondazione IRCCS Policlinico San Matteo di PaviaNCT03481972Written as Doxycycline and tauroursodeoxycholic acid
- Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALSActive, not recruitingPhase 3Humanitas Mirasole SpANCT03800524Written as Tauroursodeoxycholic Acid
- A Trial of Bile Acid Supplementation in Patients With Multiple SclerosisCompletedPhase 1/2Johns Hopkins UniversityNCT03423121Written as Tauroursodeoxycholic Acid
- Open Label Extension of TUDCA-ALS StudyStatus unknownPhase 3Humanitas Mirasole SpANCT05753852Written as Tauroursodeoxycholic Acid
- Effects of TUDCA on Endothelial Function in Type 2 DMTerminatedNot applicableBoston UniversityNCT03462940Written as Tauroursodeoxycholic acid
- The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.Status unknownEarly Phase 1The First Affiliated Hospital with Nanjing Medical UniversityNCT04727320Written as Tauroursodeoxycholic acid
- Doxycycline and TUDCA in Patients With Transthyretin Amyloid CardiomyopathyCompletedPhase 1/2Brigham and Women's HospitalNCT01855360Written as Tauroursodeoxycholic Acid and Doxycycline
- Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin ResistanceCompletedNot applicableWashington University School of MedicineNCT01877551Written as Tauroursodeoxycholic acid
- Trial of Tauroursodeoxycholic Acid (TUDCA) in AsthmaTerminatedPhase 1University of VermontNCT03878654Written as Tauroursodeoxycholic Acid
- Effect of Endoplasmic Reticulum Stress on Metabolic FunctionCompletedNot applicableWashington University School of MedicineNCT00771901Written as tauroursodeoxycholic acid
- Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular FunctionCompletedNot applicableUniversity of Missouri-ColumbiaNCT03331432Written as Tauroursodeoxycholic acid
- The Discovery of the Double Sphincter in GallbladderStatus unknownPhase 4The First Affiliated Hospital of Guangzhou Medical UniversityNCT01998451Written as Tauroursodeoxycholic acid
- Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin AmyloidosisCompletedPhase 2Fondazione IRCCS Policlinico San Matteo di PaviaNCT01171859Written as Doxycycline + Tauroursodeoxycholic acid
Codes
What other systems call ursodoxicoltaurine · ClinicalTrials.gg INT002962
- MeSH (NLM) C031655ursodoxicoltaurineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 60EUX8MN5XTAURURSODIOLConfirmed FDA, NLM
- RxNorm 2613950One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031655 | ursodoxicoltaurine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 60EUX8MN5X | TAURURSODIOL | Confirmed FDA, NLM |
| RxNorm | 2613950 | — | One source FDA |
Also registered as chenyl taurine sodium (UNII P2SD3PHQ3Y).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.